|Bid||28.55 x 1300|
|Ask||28.52 x 800|
|Day's Range||28.37 - 29.12|
|52 Week Range||26.00 - 42.50|
|Beta (3Y Monthly)||1.58|
|PE Ratio (TTM)||42.25|
|Earnings Date||May 7, 2019 - May 13, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.40|
Analysts at UBS on Friday downgraded shares of Biogen Inc. to neutral from buy, while cutting their price target on the stock to $242 from $395. "The failure of aducanumab leaves Biogen with a lack of visibility around a path back to top-line growth, and increasingly present threats to the base-business that investors had been willing to look past given the promise of Alzheimer's," analysts led by Carter Gould wrote. He cited competition to spinal muscular atrophy drug Spinraza from Roche Holding's ridiplam and threats to a 2028 patent on the company's multiple sclerosis drug Tecfidera, which is under review by trademark officials after competitor Mylan N.V. filed a patent challenge in July. Biogen's stock, which fell 1.5% in premarket trade Friday, plunged 29% on Thursday after the company announced it would be discontinuing Phase 3 trials for aducanumab, its much-hyped Alzheimer's drug. Shares of the drugmaker have fallen 25% in the year to date, while the S&P 500 has gained 13.9%.
Mylan N.V. said on Monday that it is voluntarily recalling two lots of its levoleucovorin injection due to the discovery of foreign particulates in the drug. Levoleucovorin is used to reduce harmful effects of methotrexate, a medication used to treat patients with osteosarcoma. It is also used in combination chemotherapy with 5-fluorouracil to treat patients with advanced metastatic colorectal cancer. Mylan said it discovered the presence of copper salts in the levoleucovorin during 12-month stability testing. Such particulates can lead to severe health complications like vasculitis, allergic reactions and pulmonary embolism. The drug maker has not received any reports of adverse events related to the recall and said it notified its distributors and customers by letter. Shares of Mylan have fallen 2.2% in the year to date, while the S&P 500 has gained 11.1%.
ROCKFORD, Ill., March 18, 2019 /PRNewswire/ -- Mylan Institutional LLC is conducting a voluntary nationwide recall of two lots (see table below) of Levoleucovorin Injection, 250 mg/25 mL tothe consumer/user level. The lots were manufactured by Alidac Pharmaceuticals Limited and distributed by Mylan Institutional LLC. The Levoleucovorin Injection is being recalled due to the presence of particulate matter identified as copper salts. The particulate matter was discovered during 12-month stability testing. Administration of a sterile injectable that has foreign particulates has the potential of severe health consequences.
Mapi Pharma Ltd., a fully integrated, clinical, late stage biopharmaceutical company, announced today that it has received complementary funding from the Israeli Ministry of the Economy to build a new sterile production plant for GA Depot injectable products. The approved financing plan is for a pioneering production plant for the manufacturing of a slow release formulation of Glatiramer Acetate (GA) (Copaxone®) for treating multiple sclerosis.
[Editor's note: This story was previously published in February 2019. It has since been updated and republished.]Overall, the stock market has made a huge improvement at the start of 2019 from where it ended in 2018; it has been a complete turnaround from last year's drop, when stocks entered bear-market territory.But even though many stocks have completely erased all of their losses and made it back into the green, not all stocks have done so well. What this means is that while there are still plenty of duds out there, there are also a few undervalued stocks to buy; it has just become a little trickier to find them amid all the flashy comeback stories.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo find the best stocks to invest in now,disciplined investors might start with their own watch list, which should contain "wish list" stocks that are usually too expensive or have been put there to be on the backburner for later. Among such stocks, companies that got left out of the rally are the most compelling. Even better, the best undervalued stocks to invest in are those that dropped by double-digit percentages during the current rally.Why is that?Markets that are pricing in the negative news typically lower the risk for investors. Such companies may work to resolve the business problem at hand, which improves its prospects and leads to a higher share price in the long run. As long as the bad news reported is a temporary setback and the business model is not broken, the risks behind buying a stock on a dip are lower. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% With all of that in mind, here are five undervalued stocks to invest in that aren't as scary as they seem. Sony (SNE)Investors expected more from Sony's (NYSE:SNE) earnings report when the company posted results on Feb. 1. Revenue of 2.4 trillion yen in the third-quarter missed estimates for 2.67 trillion yen.Adding salt to the wound, many SNE investors are fretting over Sony's weaker sales outlook, with smartphone and camera sales lagging. On the flipside, the PlayStation 4 business still could rebound. Even though the console cycle is many years old, customers will continue to buy new game titles. And in the smartphone space, a refresh in the second half of this year may give customers a reason to buy a new Sony device again.Sony is clearly not a broken company, so the stock's drop from $50 on Feb. 1 to $46 appears overdone. Trading less than 10% above its 52-week low and about 25% below its 52-week high, Sony stock clearly deserves its spot among the best undervalued stocks to consider now. Celestica (CLS)Celestica (NYSE:CLS) reported fourth-quarter revenue of $1.73 billion, up 10% from last year. Net earnings rose $46.5 million to $60.1 million, bringing in earnings of 44 cents a share. However, investors were unimpressed with the weak sequential revenue in its Communications, ATS and CCS segments, which were either flat or down. Still, revenue from all segments grew in the double digits from last year.Celestica ended the year with $422 million in cash and cash equivalents. Net cash fell $335 million for the year. And the balance sheet is not as strong as it could be, with non-IFRS debt leverage at 2.6X.The company supplies equipment in ATS -- aerospace and defense, industrial, smart energy, health tech and capital equipment. Its enterprise unit consists of servers and storage. Why then, should investors believe the company will offset the weakness it faces in the eroding semiconductor market?Celestica is cutting costs in operations to align the business with the lower revenue. It will continue to build its capital equipment business. Management believes the fundamentals in this space will only improve in the long run. As next-generation adoption in display continues, its OLED business, for example, will add to its bottom line.Celestica stock is an undervalued play worth considering. Allergan (AGN)Generic drug supplier Allergan (NYSE:AGN) fell over 10% in late January and early February for two reasons. First, its fourth-quarter earnings report did not please investors. Operating income sank 11.8% year-over-year, and revenue fell 5.8% YoY to $4.08 billion.On Feb. 1, the Food and Drug Administration approved Evolus' (NASDAQ:EOLS) Jeuveau. This product competes directly with Allergan's Botox. Pricing could come in at 20% below that of Botox, putting pressure on Allergan's bottom line.Be warned: it's likely that AGN stock will continue to sell off as investors price in the worst case scenario for Botox. Even though management already expects some pricing erosion, it is confident that the sales volume will taper off slowly. But this is good news for investors in search of a bargain, as the more the stock falls, the more discount value investors get on AGN stock.As Allergan launches new products this year, it will offset the negative impact of generic drug competition for Botox, making it an undervalued stock to watch. Innoviva (INVA)Innoviva (NASDAQ:INVA) is another stock in the drug space whose large drop starting in late January appears greatly overdone. The market all but erased the powerful uptrend in the stock that began after INVA sold off in November 2018 and bottomed at $14.The FDA approved Mylan's (NASDAQ:MYL) generic version of Advair, which GlaxoSmithKline (NYSE:GSK) produces. This forced investors to worry about Innoviva's prospects because the company is paid royalties from Glaxo. In the third quarter, Innova received $65.1 million in royalty revenues from Glaxo; $51.7 million came from global net sales of Revar/Breo Ellipta.On Feb. 6, Innoviva reported revenue of $79.86 million, up 14.9% from last year. With the stock trading at a forward price-to-earnings ratio of 7.7, the price-earnings-to-growth ratio is 0.39. As such, this general pessimism has created an appealing entry point to INVA stock. * 7 Winning High-Yield Dividend Stocks With Payouts Over 5% Investors appear to be overreacting to the generic competition. If demand for Innoviva's formulation does not drop and prices hold, royalty revenues should not fall as much as markets think, which makes INVA an ideal undervalued stock to invest in now. Vodafone (VOD)Telecom stocks are out of favor. For example, just look at AT&T (NYSE:T), which is down over 20% from its 52-week high. But Vodafone (NASDAQ: VOD) is down the most among the major names in the sector, falling over 40% from its 52-week high.Third-quarter results for VOD, which ended on Dec. 31, missed analysts' consensus sales forecasts. Vodafone continued to under-perform in Europe, due to rising competition. Although the company highlighted improving customer trends in Italy, Germany, and reduced churn in Spain, this was not enough to prevent revenue falling 5.6% in Europe and 6.8% overall.With all that bad news, it is little wonder why the stock has been marching lower. But VOD still has ways to mend the wound. The company could trim the dividend and re-allocate its resources toward advertising and capital expenditures. That would put it in a better position to compete with its European counterparts. And the stock would respond if those efforts lead to better revenue numbers.Vodafone shares pay a dividend yield in excess of 6%. If Vodafone grows its U.K. business as it signs on users to its 5G services and cuts costs as it signs on more customers, VOD stock will finally move higher.As of this writing, Chris Lau owned shares of Innoviva. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 15 Stocks Sitting on Huge Piles of Cash * The 10 Best Stocks to Buy for the Bull Market's Anniversary * 7 Dividend Stocks With Big Yields Compare Brokers The post 5 Undervalued Stocks to Invest In appeared first on InvestorPlace.
The repercussions can be seen in spreads, the risk premium investors pay above Treasuries to own bonds in the sector. Health care has underperformed the high-grade market this year, narrowing just 19 basis points since January. The Bloomberg Barclays U.S. IG Corporate Bond Index, by contrast, has narrowed by 32 basis points year-to-date.
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
NV said the Securities and Exchange Commission closed a three-year-old investigation into real-estate dealings with a former director, without taking any enforcement action. The SEC had been looking into whether Mylan failed to properly disclose real-estate deals involving the company and its then-lead outside director, who has since left the board. The SEC issued a subpoena in the matter in September 2015.
The U.S. Food and Drug Administration on Tuesday approved a new generic of heart medicine valsartan and said it prioritized the drug's review to help relieve recent shortage as manufacturers around the ...
Mylan NV NASDAQ/NGS:MYLView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for MYL with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MYL. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding MYL totaled $3.79 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
As some stocks get cheaper, and others get pricier, AllianceBernstein offers a compelling case for seeking out low valuation equities right now.
HERTFORDSHIRE, England and PITTSBURGH and SAN JUAN, Puerto Rico, March 7, 2019 /PRNewswire/ -- A small crowd of SBP staff, AmeriCorps members, Puerto Rico Central Office of Recovery and Reconstruction's Omar J. Marrero, Esq and volunteers from global pharmaceutical company Mylan (MYL) gathered in a quiet backyard in Villa Palmeras to celebrate the homecoming of Hurricane Maria survivor Ms. Sunchy. While Sunchy and her family's recovery may be over, SBP is rebuilding for many other Puerto Rican families thanks to a major gift from the Mylan Charitable Foundation. "Mylan has a long-established commitment to the people of Puerto Rico, having run operations on the island for more than 30 years," said Mylan CEO Heather Bresch.
FDA chief Scott Gottlieb on Tuesday unexpectedly announced his resignation from the agency. Under Gottlieb's tenure the FDA approved 59 new drugs last year, and a record 971 generic drugs. The biotech sector is on pace for its worst weekly decline since December, weighed down in part by uncertainty following this week's surprise announcement from Food And Drug Administration Commissioner Scott Gottlieb that he will be stepping down next month.
NEW YORK, March 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Wall Street was set to dip at the open on Wednesday in the absence of fresh developments on trade, with investors taking a step back after a strong run in equities since the start of the year. Hopes that the United States and China will end their bitter trade row and a dovish stance on future interest rate hikes by the Federal Reserve has propelled the S&P 500 11 percent higher this year.
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Performance in fiscal 2018In fiscal 2018, Mylan (MYL) reported revenues of $11.43 billion, a YoY decline of 4%. The company reported adjusted EPS of $4.58, a YoY
J.P. Morgan maintaining $6 price target on General Electric Bank of America lowering price target on General Electric to $12 from $13 Cowen downgrading Tripadvisor to underperform from market perform Goldman downgrading VMware to sell from neutral Morgan Stanley downgrading Teva Morgan Stanley upgrading MylanHere are the biggest calls on Wall Street Tuesday: J.
FDA Commissioner Scott Gottlieb is resigning from his post. During his tenure, generic drug approvals soared. The FDA also approved its first gene therapy under his administration.
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Capex projectionsIn fiscal 2018, Pfizer (PFE) and Mylan (MYL) reported capital expenditures of $2.04 billion and $252.10 million, respectively. Wall Street analysts
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Dividend projections In fiscal 2018, Pfizer (PFE) reported dividends per share of $1.36, which amounted to a total dividend payment on common stock worth $8.0
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter earnings investor presentation, Pfizer (PFE) forecasted its fiscal 2019 adjusted SI&A (selling,
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Earnings guidance for fiscal 2019In its fourth-quarter earnings conference call, Pfizer (PFE) forecasted its fiscal 2019 non-GAAP diluted EPS to fall in the range
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?(Continued from Prior Part)Revenue guidance for fiscal 2019In its fourth-quarter earnings conference call, Pfizer (PFE) forecasted that its fiscal 2019 revenues would fall in the range of $52
Is Pfizer or Mylan a Better Pharmaceutical Pick Right Now?Stock price movements On February 28, Pfizer (PFE) closed at $43.35, 0.98% higher than its previous closing price, 26.31% higher than its 52-week low of $34.32, and 6.71% below its 52-week